Design, synthesis and anticolorectal cancer activity of 2- bromoalkoxyanthraquinones
The impact of alkoxy chain length and the presence of a 1-hydroxy group in synthesised 2-bromoalkoxyanthraquinones was evaluated against HCT116, HT29, and CCD841 CoN cell lines. Molecular docking was employed to elucidate the interactions between these compounds and potential p53 and KRAS targets...
Saved in:
Main Authors: | , , , , , , , , |
---|---|
Format: | Conference or Workshop Item |
Language: | English English |
Published: |
2024
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/45060/1/Lee%20Yean%20Kee-ACP2023-Abstract.pdf http://eprints.um.edu.my/45060/2/Lee%20Yean%20Kee-ACP2023-Poster.pdf http://eprints.um.edu.my/45060/ https://icceoca16.sg/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Universiti Malaya |
Language: | English English |
Summary: | The impact of alkoxy chain length and the presence of a 1-hydroxy group in
synthesised 2-bromoalkoxyanthraquinones was evaluated against HCT116, HT29,
and CCD841 CoN cell lines. Molecular docking was employed to elucidate the
interactions between these compounds and potential p53 and KRAS targets. Results
indicated that 2-bromoalkoxyanthraquinones with the 1-hydroxy group exhibited
greater anticancer activity compared to their counterparts. Specifically, compound 6b
bearing C3 alkoxy chain displayed the most promising antiproliferation activity
against HCT116 cells (IC50 = 3.83 ± 0.05 μM) and demonstrated high selectivity for
HCT116 over CCD841 CoN cells (SI = 45.47). Molecular docking analysis revealed
additional hydrogen bonds between the 1-hydroxy group of 6b and the proteins.
Compound 6b also exhibited adequate lipophilicity (cLogP = 3.27) and ligand
efficiency metrics (LE = 0.34; LLE = 2.15) within the acceptable range for an initial
hit. This study underscores the potential of the 1-hydroxy group and a short alkoxy
chain in enhancing the anti-colorectal cancer activity of 2-bromoalkoxyanthraquinones.
Further optimisation should be possible for compound 6b as a potential
therapeutic agent against colorectal cancer. |
---|